Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.53 |
| ▸ | CA2 | P00918 | 11/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 10/20 | 0.50 |
| ▸ | CA12 | O43570 | 9/20 | 0.50 |
| ▸ | CA4 | P22748 | 6/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276221 | 0.87 | CA1 (0.54) | CA1CA2PDE4APDE4BPDE4C | |
| SCHEMBL595494 | 0.86 | CA1 (0.56) | CA1CA2PDE4APDE4BPDE4C | |
| SCHEMBL596472 | 0.85 | PDE4A (0.58) | CA1CA2PDE4APDE4BPDE4C | |
| SCHEMBL5583215 | 0.85 | PDE4A (0.58) | CA1CA2PDE4APDE4BPDE4C | |
| SCHEMBL3255012 | 0.82 | CA1 (0.49) | CA1CA2CA9CA12CA4 | |
| SCHEMBL13429353 | 0.80 | CA1 (0.60) | CA1CA2CA9CA12CA4 | |
| SCHEMBL8076402 | 0.80 | CA1 (0.62) | CA1CA2PDE4APDE4BPDE4C | |
| SCHEMBL2278403 | 0.80 | CA1 (0.47) | CA1CA2CA9CA12CA4 | |
| SCHEMBL2286421 | 0.77 | CA1 (0.47) | CA1CA2CA9CA12CA4 | |
| SCHEMBL12375090 | 0.76 | CA1 (0.46) | CA1CA2CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258819-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9682092-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150216885-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, LLC | 2015-08-06 | — | — | US | disclosed |
| US-9029353-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-8501712-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120264714-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216885-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, TNF | CA1 1986/4885CA2 886/4885PDE4A 1336/4885 |
| US-20120264714-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, TNF | CA1 1986/4885CA2 886/4885PDE4A 1336/4885 |
| US-20170258819-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, TNF | CA1 1986/4885CA2 886/4885PDE4A 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.